TWI511737B - 可用於治療多種皮膚病之衍生自人類c-x-c趨化因子之四胜肽 - Google Patents
可用於治療多種皮膚病之衍生自人類c-x-c趨化因子之四胜肽 Download PDFInfo
- Publication number
- TWI511737B TWI511737B TW103120387A TW103120387A TWI511737B TW I511737 B TWI511737 B TW I511737B TW 103120387 A TW103120387 A TW 103120387A TW 103120387 A TW103120387 A TW 103120387A TW I511737 B TWI511737 B TW I511737B
- Authority
- TW
- Taiwan
- Prior art keywords
- skin
- composition
- peptide
- peptides
- seq
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 28
- 108050006947 CXC Chemokine Proteins 0.000 title description 16
- 102000019388 CXC chemokine Human genes 0.000 title description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 127
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 59
- 239000000203 mixture Substances 0.000 claims description 53
- 208000027418 Wounds and injury Diseases 0.000 claims description 37
- 206010052428 Wound Diseases 0.000 claims description 34
- 201000004681 Psoriasis Diseases 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 20
- 239000002537 cosmetic Substances 0.000 claims description 14
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 12
- 201000008937 atopic dermatitis Diseases 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 230000032683 aging Effects 0.000 claims description 11
- 201000004624 Dermatitis Diseases 0.000 claims description 10
- 206010040925 Skin striae Diseases 0.000 claims description 10
- 208000031439 Striae Distensae Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 230000004968 inflammatory condition Effects 0.000 claims description 10
- 241000220317 Rosa Species 0.000 claims description 9
- 239000006210 lotion Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 231100000397 ulcer Toxicity 0.000 claims description 9
- 208000025865 Ulcer Diseases 0.000 claims description 8
- 210000004209 hair Anatomy 0.000 claims description 8
- 231100000241 scar Toxicity 0.000 claims description 8
- 208000032544 Cicatrix Diseases 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 7
- 230000037387 scars Effects 0.000 claims description 7
- 208000034656 Contusions Diseases 0.000 claims description 6
- 230000009519 contusion Effects 0.000 claims description 6
- 210000004400 mucous membrane Anatomy 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 239000000443 aerosol Substances 0.000 claims description 5
- 230000037314 wound repair Effects 0.000 claims description 5
- 208000010201 Exanthema Diseases 0.000 claims description 4
- 238000005299 abrasion Methods 0.000 claims description 4
- 201000005884 exanthem Diseases 0.000 claims description 4
- 206010037844 rash Diseases 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 150000008574 D-amino acids Chemical class 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 61
- 210000002510 keratinocyte Anatomy 0.000 description 48
- 102000019034 Chemokines Human genes 0.000 description 36
- 108010012236 Chemokines Proteins 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 36
- 210000001519 tissue Anatomy 0.000 description 32
- 239000002243 precursor Substances 0.000 description 21
- 238000000034 method Methods 0.000 description 20
- 230000033115 angiogenesis Effects 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 229920002683 Glycosaminoglycan Polymers 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 16
- 238000009472 formulation Methods 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 230000029663 wound healing Effects 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000003102 growth factor Substances 0.000 description 10
- 230000035876 healing Effects 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 102000004889 Interleukin-6 Human genes 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 8
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 8
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 7
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 210000000440 neutrophil Anatomy 0.000 description 7
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 229910002091 carbon monoxide Inorganic materials 0.000 description 6
- 230000012292 cell migration Effects 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 239000012737 fresh medium Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 230000000770 proinflammatory effect Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 6
- -1 9-fluorenylmethoxycarbonyl Chemical group 0.000 description 5
- 102000005600 Cathepsins Human genes 0.000 description 5
- 108010084457 Cathepsins Proteins 0.000 description 5
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 5
- 108010013639 Peptidoglycan Proteins 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 5
- 229960002882 calcipotriol Drugs 0.000 description 5
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 210000003780 hair follicle Anatomy 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000000475 sunscreen effect Effects 0.000 description 4
- 239000000516 sunscreening agent Substances 0.000 description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
- 210000003606 umbilical vein Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
- 229920002971 Heparan sulfate Polymers 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 206010040943 Skin Ulcer Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000035784 germination Effects 0.000 description 3
- 230000036074 healthy skin Effects 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000029774 keratinocyte migration Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000003001 serine protease inhibitor Substances 0.000 description 3
- 230000037380 skin damage Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 101001027327 Bos taurus Growth-regulated protein homolog alpha Proteins 0.000 description 2
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 description 2
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 2
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 208000005230 Leg Ulcer Diseases 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003255 anti-acne Effects 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003212 astringent agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 239000002852 cysteine proteinase inhibitor Substances 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000008472 epithelial growth Effects 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000029226 lipidation Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001185 psoriatic effect Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 239000002884 skin cream Substances 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 238000013334 tissue model Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- QWVUOVZJBNQSNS-UHFFFAOYSA-N (+-)-Tropan-3endo,6exo-diol Natural products C1C(O)CC2C(O)CC1N2C QWVUOVZJBNQSNS-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- LPEKGGXMPWTOCB-UHFFFAOYSA-N 8beta-(2,3-epoxy-2-methylbutyryloxy)-14-acetoxytithifolin Natural products COC(=O)C(C)O LPEKGGXMPWTOCB-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000349 Acanthosis Diseases 0.000 description 1
- 108091005508 Acid proteases Proteins 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102100038326 Beta-defensin 4A Human genes 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100021942 C-C motif chemokine 28 Human genes 0.000 description 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 1
- 102100039396 C-X-C motif chemokine 16 Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 108010014419 Chemokine CXCL1 Proteins 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102100035298 Cytokine SCM-1 beta Human genes 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 108010015972 Elafin Proteins 0.000 description 1
- 102000002149 Elafin Human genes 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 102100020997 Fractalkine Human genes 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000897477 Homo sapiens C-C motif chemokine 28 Proteins 0.000 description 1
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 1
- 101000889133 Homo sapiens C-X-C motif chemokine 16 Proteins 0.000 description 1
- 101000804771 Homo sapiens Cytokine SCM-1 beta Proteins 0.000 description 1
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 description 1
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 description 1
- 101001052490 Homo sapiens Mitogen-activated protein kinase 3 Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100035304 Lymphotactin Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 description 1
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101710180313 Protease 3 Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 102100040312 Ribonuclease 7 Human genes 0.000 description 1
- 108010085025 Ribonuclease 7 Proteins 0.000 description 1
- 102000013674 S-100 Human genes 0.000 description 1
- 108700021018 S100 Proteins 0.000 description 1
- 102000005871 S100 Calcium Binding Protein A7 Human genes 0.000 description 1
- 108010005256 S100 Calcium Binding Protein A7 Proteins 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- 206010067723 Skin plaque Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010066409 Staphylococcal skin infection Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000006427 angiogenic response Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 108050002883 beta-defensin Proteins 0.000 description 1
- 102000012265 beta-defensin Human genes 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229910000420 cerium oxide Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000004031 devitrification Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- MDCUNMLZLNGCQA-HWOAGHQOSA-N elafin Chemical compound N([C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]2CSSC[C@H]3C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)NCC(=O)N[C@H](C(N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]5N(CCC5)C(=O)[C@H]5N(CCC5)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N4)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N3)=O)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N MDCUNMLZLNGCQA-HWOAGHQOSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000019305 fibroblast migration Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000005255 gram-positive cell Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000049262 human DEFB4A Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000037231 joint health Effects 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000008949 local secretion Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940057867 methyl lactate Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- CGIHFIDULQUVJG-UHFFFAOYSA-N phytantriol Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)(O)C(O)CO CGIHFIDULQUVJG-UHFFFAOYSA-N 0.000 description 1
- CGIHFIDULQUVJG-VNTMZGSJSA-N phytantriol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@@](C)(O)[C@H](O)CO CGIHFIDULQUVJG-VNTMZGSJSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000013155 positive regulation of cell migration Effects 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 208000006155 precocious puberty Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000001273 protein sequence alignment Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229940030793 psoriasin Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000023650 regulation of keratinocyte proliferation Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000020874 response to hypoxia Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
- A61Q7/02—Preparations for inhibiting or slowing hair growth
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Birds (AREA)
- Toxicology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Description
本申請案主張對於2013年6月14日申請之美國臨時申請案第61/835,424號之優先權之益處,其以引用方式全文併入本文中。
本發明係關於具有生物、化妝品及治療活性之四胜肽。特定而言,本發明係關於衍生自若干C-X-C趨化因子之保守區之四胜肽。該等胜肽已顯示促進細胞遷移、血管生成、中和細菌細胞組份(例如LTA誘導之促發炎性信號)、並刺激正常表皮皮膚替代物之活性。本發明進一步係關於使用該等胜肽促進傷口修復並治療多種影響皮膚及其他相關體表(例如口腔)之傷害之方法。
角質細胞及真皮內皮細胞為調控皮膚傷口及潰瘍之癒合之可溶性因子之主要來源。因降低之活性導致之異常(包括生長因子產生、血管生成反應、巨噬細胞功能、膠原累積、表皮障壁功能及角質細胞及纖維母細胞遷移及增殖)均有助於缺陷性傷口癒合。生長因子及細胞因子已用於供治療傷口之臨床環境。實例包括(但不限於)已顯示對罹患不同病因之多種傷口及慢性皮膚潰瘍之患者之傷口癒合發揮有益效應的PDGF(血小板源生長因子(Rees等人,1999)及GM-CSF(粒細胞-巨噬細胞群落刺激因子),該等病因包括羥基脲相關之腿潰瘍(Stagno
等人,1999)、靜脈腿潰瘍(Da Costa等人,1999)、血紅素病相關之潰瘍(Voskaridou等人,1999)及由切除術導致之傷口(Gaches等人,1998)。向患有皮膚病灶之麻風患者真皮內投與GM-CSF亦導致傷口癒合增強及角質細胞之數量及層增加(Kaplan等人,1992;Braunstein等人,1994)。
生長因子及細胞因子二者均為蛋白質。使用蛋白質治療劑治療表皮傷口之困難常與所涉及蛋白質之大尺寸相關。天然蛋白質之複雜結構及製造成本對於廣泛臨床用途而言令人望而卻步。調配物中之該等天然蛋白質之穩定性及相容性亦為主要問題。因天然蛋白質之大尺寸而滲透到達皮膚之標靶層之能力較差常減少效力並解釋蛋白質治療劑之失敗有益效應。為克服該等問題,攜帶大蛋白質之活性之短胜肽應滿足較不昂貴、成本有效之產生以及處置及操縱簡單之需求。另外,短生物活性胜肽因對蛋白酶較不敏感而由傷口組織較好地吸收並保留。短生物活性胜肽之吸收特徵之優勢亦使其成為除護理急性及慢性傷口以外之用途、例如治療與老化及日曬相關之皮膚問題之可行選擇。
趨化因子在結構上相關並代表具有不同生物活性之8kd至150kd蛋白質之較大超家族。其通常在細胞刺激時分泌來在體內恆定期間以及在發炎期間控制白血球運輸,且對於先天性與適應性免疫間之聯繫係必要的。連同諸如整合素及選擇蛋白等黏著分子,趨化因子及其受體主要用作促進具體細胞類型選擇性移動至靶向組織微環境中並移動出該微環境的複雜分子網絡之一部分(Key等人,2003;Ono等人,2003)。趨化因子選擇性介導嗜中性球、巨噬細胞及淋巴球之區域特異性募集。除了為趨化性因子以外,趨化因子亦在體內恆定之維持、血管生成/血管抑制、細胞分化及活化、傷口癒合、腫瘤生長及轉移、淋巴組織之淋巴球歸巢及發育以及影響免疫反應之總體1型/2型
平衡方面起重要作用(Behm等人,2012;Gillitzer等人,2001;Raman等人,2011;Romagnani等人,2004;Rossi等人,2000)。
藉由四半胱胺酸模體來定義,根據其胺基末端處之半胱胺酸殘基之構型將趨化因子細分為四個不同家族。有兩個較大亞家族CCL亞家族(CCL1至CCL28)及CXCL亞家族(CXCL1至CXCL16)以及兩個較小亞家族XCL亞家族(XCL1至XCL2)及CX3CL1亞家族(Bacon等人,2003)。趨化因子之CXC亞家族在不同過程(包括發炎、傷口癒合、生長調控、血管生成及腫瘤生成)中起重要作用(Keeley等人,2008;2011)。許多趨化因子與內皮細胞及細胞外基質上之蛋白聚糖之糖胺聚糖(GAG)部分相互作用(Handel等人,2005)。充當硫酸肝素之模型化合物之肝素係在體內實際上每一細胞上表現之最普遍之GAG類別。所有趨化因子均與肝素GAG相互作用。
在吾人研究中,注意到C-X-C趨化因子在其一級胺基酸序列中顯示一些序列類似性但在二級結構中高度保守。九種人類C-X-C趨化因子之一級胺基酸序列之檢查使用下文「本發明之詳細說明,第1段落」中顯示之每一趨化因子之NCBI登錄號揭露定位於處C末端部分處之參與GAG結合之高度保守區。吾人自GAG結合區生成四胜肽並測試生物活性。令人驚奇地,該等四胜肽顯示不同生物活性,包括促進角質細胞遷移、誘導人類臍靜脈內皮細胞上之血管生成、中和LTA誘導之促發炎性細胞因子,及調節細胞生長及生長因子產生。該等四胜肽可用作用於改良多種皮膚病之醫藥及化妝品產物二者。
本發明係關於可用於促進哺乳動物之傷口癒合之短生物活性胜肽。較佳藉由分離胜肽靶向之傷口為影響皮膚及相關黏膜表面之彼等。儘管並不限於任何特定機制,但本發明胜肽能夠藉由刺激細胞遷移及血管生成來影響傷口癒合。本發明胜肽可以活體外及活體內方式
二者使用,且能夠誘導角質細胞之前述活性。
本發明之一實施例係關於式(I或V)-X1
-K-X2
之分離四胜肽,其中X1可選自E、Q及K;且X2可選自M、F、I、W、V及L。分離胜肽可含有胺基酸之L-或D-鏡像異構物形式或其組合。根據本發明之再一實施例,分離胜肽可偶聯至載體蛋白,或經由利用脂肪酸進行C末端醯胺化或N末端醯化(即,脂化)來改質。當施加至皮膚及其傷口時,該等添加增強胜肽之生物活性。
根據本發明之某些較佳實施例,該等分離胜肽均在3位處含有離胺酸。分離胜肽之具體實施例包含SEQ ID NO:1、2、3、4、5、6及7,其均顯示對細胞遷移之刺激活性並影響傷口修復。
下文所顯示之所衍生四胜肽適合式(I或V)-X1
-K-X2
,其中X1可選自E、Q及K;且X2可選自M、F、I、W、V及L。
本發明之另一實施例係關於含有醫藥上或美容上可接受之載體及一或多種前述胜肽之治療或化妝品組合物。前述組合物可用於製造用於在使哺乳動物之皮膚傷口癒合之應用中使用之藥品或化妝品組合物。該等組合物中之胜肽較佳濃度在約0.1μg/mL至約500μg/mL或約0.1μg/mL至約20mg/mL之範圍內。組合物之較佳形式為氣溶膠、乳液、液體、溶液、洗劑、乳膏、膏糊、油膏、粉劑、凝膠及發泡體。
另外,本發明之胜肽及含有其之組合物可提供納入一般皮膚護理及化妝品調配物中之有用特性,該等調配物係例如多種皮膚化妝品、皮膚乳膏、洗劑、防曬液及治療洗劑或乳膏,例如用於雷射程序後護理之抗痤瘡調配物。
本發明亦係關於使用前述組合物用於癒合哺乳動物之傷口。通常,該治療方法需要向傷口及或發炎性病狀、尤其皮膚(表皮)及相關黏膜組織之彼等投與有效量之含胜肽組合物並持續有效時間量。該等傷口包括外科傷口、擦傷、水皰、燒傷、撕裂、潰瘍、挫傷、皮疹、瘢痕、妊娠紋及由於老化及環境暴露之內在及外在效應導致之皮膚損害,包括起皺紋、皮膚下垂及光損害。發炎性皮膚病包括牛皮癬、異位性皮膚炎及玫瑰斑及因去除毛髮引起之發炎。
趨化因子調節傷口癒合、發炎性/抗發炎性及血管生成/血管抑制活性。其藉由結合至白血球上之受體之G蛋白偶合受體(GPCR)類別及標靶組織中之細胞表面糖胺聚糖(GAG)來發揮其功能。趨化因子與GAG之結合係藉由GAG上之帶負電荷之鏈與趨化因子中之鹼性殘基團簇之相互作用生成之離子力來介導(Handel等人,2005)。在活體內,該情況更加複雜,且已報導趨化因子藉由產生固定化或趨觸性梯度來起作用,該梯度引導細胞至發炎部位之遷移(Proudfoot,2006)。GAG-趨化因子相互作用可在沿細胞外基質確立梯度中起關鍵作用且可促進趨化因子與其G蛋白質偶合受體之結合。GAG或硫酸肝素(HS)蛋白聚糖亦可作為信號傳導之功能性趨化因子共同受體起作用,從而導致形成GAG/趨化因子及趨化因子受體之三元錯合物(Handel等人,2005)。關於具體趨化因子之研究已映射GAG與趨化因子之結合位
點。在9種人類C-X-C趨化因子前體蛋白質(包括GRO-α前體(CXCL-1)、趨化因子2前體(CXCL-2)、趨化因子3前體(CXCL-3)、趨化因子4前體(CXCL-4)、趨化因子5前體(CXCL-5)、趨化因子6前體(CXCL-6)、IL-8前體(CXCL8)、趨化因子9前體(CXCL-9)、趨化因子11前體(CXCL-11))之保守GAG結合位點之一級胺基酸序列之密切檢查中,發現尤其感興趣之保守四胜肽區。此研究中所定義之保守四胜肽段係定位於部分GAG結合區內。下文係選定人類C-X-C趨化因子前體之C末端序列之比對之示意性說明並突出短四胜肽。比對係使用NCBI網站(ncbi.nlm.nih.gov)上關於之多個蛋白質序列比對之COBALT程式生成。僅顯示比對中之每一趨化因子之C末端部分且數字為序列中之殘基之開端及末端。A.GRO-α前體(NCBI登錄號P09341.1);B.趨化因子2前體(NCBI登錄號NP_002080.1);C.趨化因子3前體(NCBI登錄號NP_002081.2);D.趨化因子4前體(NCBI登錄號P80162.4);E.趨化因子5前體(NCBI登錄號NP_002985.1);F.趨化因子6前體(NCBI登錄號NP_002984.1);G.IL-8前體(NCBI登錄號);H.趨化因子9前體(NCBI登錄號NP_002407.1);I.趨化因子11前體(NCBI登錄號EAX05774.1)。
比對中顯示在CXC趨化因子中高度保守之短四胜肽模體。*指示趨化因子之部分GAG結合位點。四胜肽顯示保守骨架I-K-。除具有纈
胺酸(V)之IL-8以外,所有其他IL-8在四胜肽模體之1位處具有異白胺酸(I)且在3處具有離胺酸(K)。因此,(I或V)-X1
-K-X2
式可用於代表所生成且在表1中所顯示之四胜肽。值得注意的係,趨化因子之GAG結合區亦參與二聚體形成,此乃因大部分CXC趨化因子可逆地以單體及二聚體形式存在,且因此募集特徵將不僅受單體-二聚體平衡常數影響且亦受單體及二聚體與標靶組織中之嗜中性球上之受體及與細胞表面及間隙空間上之GAG的結合相互作用影響(Gangavarapu等人,2012)。
下文所顯示之所衍生四胜肽適合式I(V)-X1
-K-X2
,其中X1可選自E、Q及K;且X2可選自M、F、I、W、V及L。
C-X-C趨化因子在其對許多細胞類型之趨化性活性方面眾所周知。為評估最新衍生之四胜肽是否具有刺激角質細胞遷移之活性,使SEQ ID NO 1、2、3、4、5、6、7及8經受角質細胞刮傷測試,即充分接受之用於評估活性化合物誘導細胞遷移及活體外傷口閉合之能力之分析。在不存在補充物以限制細胞增殖之無血清角質細胞生長培養基中實施實驗。在所指示時間藉由相位差顯微術檢查受傷區域。如表1中所顯示,四胜肽顯著誘導刮傷閉合。在20μg/ml下,與經PBS處理之傷口(以其為100%)相比,藉由SEQ ID 1、2、3、4、5、6及7誘導之
傷口閉合之百分比在165%至240%之範圍內(表1)。隨機生成之胜肽SEQ ID NO 8不誘導細胞遷移及刮傷閉合。為證實胜肽在針對刮傷閉合所測試之濃度下對角質細胞無毒,使所有胜肽經受MTT細胞毒性測試。在高達500ug/ml之濃度下培育24hr後,任一胜肽對活體外正常皮膚角質細胞均無細胞毒性。總而言之,與經PBS處理之對照細胞之百分比相比,利用四胜肽SEQ ID NO 1至7處理顯著誘導正常人類表皮角質細胞至刮傷區域中之遷移,如藉由7hr處理後受傷區域之閉合之百分比所指示。
血管生成(即自已存在血管網絡形成新的毛細血管)係傷口修復之基本步驟。本發明中所生成之胜肽SEQ ID NO 1至7亦刺激毛細血管形成。活體外血管生成分析使用人類臍靜脈內皮細胞(HUVEC)量測一系列導致形成新的毛細血管之事件。在誘導時,HUVEC進行遷移以對準,然後自個別細胞發芽。發芽事件導致形成新的毛細血管,其進一步發育以形成閉合多邊形。最終,發育成複雜網狀結構。人類組織蛋白酶抑制素(cathelicidin)L-37係經充分研究之促進血管生成之實例。其在評估中用作陽性對照。新的毛細血管之發芽僅在利用LL-37處理3hr後即變得可視(表2)。在利用LL-37處理5hr後,形成閉合多邊形。與LL-37相比,SEQ ID NO.1、2、3、4、5、6及7誘導HUVEC之類似變化,從而在3hr及5hr處理下導致新的毛細血管形成及複雜多邊形結構(表2)。相比之下,隨機生成之胜肽SEQ ID NO 8(KMG)及PBS在觀測到LL-37及本發明胜肽之血管生成活性時不誘導該變化(表2)。
眾所周知革蘭氏(Gram)陽性細胞壁組份肽聚糖(PGN)刺激促發炎性細胞因子表現。脂磷壁酸(LTA)係引起包括氧化氮合成酶(iNOS)、環氧合酶-2(COX-2)、IL-1 β、TNF-α及IL-6上調之促發炎性信號之濃度-及時間依賴性增加之PGN中之關鍵分子(Lin等人,2010)。因此吾人利用本發明胜肽預處理LTA且然後評估在與人類皮膚角質細胞接觸
時之IL-6刺激活性。如表3中所顯示,利用SEQ ID NO 1、2、3、4、5、6及7預處理LTA顯著降低人類皮膚角質細胞培養物中之LTA刺激之IL-6表現之量,此表明該等胜肽可中和游離LTA之毒性效應。極為可能的係,四胜肽之帶正電荷之殘基結合至帶負電荷之LTA,從而阻斷LTA與其受體之相互作用。此係顯著的,此乃因細菌細胞壁組份已參與發炎性皮膚病,例如痤瘡、玫瑰斑、異位性皮膚炎等。
細胞增殖之調節係傷口修復中之另一重要步驟。吾人測試本發明胜肽對人類皮膚角質細胞之增殖活性。與刮傷測試、血管生成及阻斷LTA誘導之IL-6表現中所量測之趨化性活性相比,本發明胜肽對角質細胞增殖之調節顯示多樣但中等之活性。SEQ ID NO 1(HB2233)顯示對角質細胞增殖之抑制性活性,SEQ ID NO 3(HB2270)亦觀測到該抑制性活性。SEQ ID NO 6似乎刺激角質細胞增殖,但該活性僅為有限。對角質細胞增殖之抑制性活性提示吾人測試TGF-β1表現,此乃因眾所周知此生長因子抑制細胞增殖。如表4中所顯示,SEQ ID NO 1及3二者在培養之角質細胞中誘導中等之TGF-β1表現量。
由MatTek公司(Ashland MA)研發之SOR-300-FT係包括正常的人類源角質細胞及牛皮癬性纖維母細胞之高度分化之活體外牛皮癬組織。在形態上,該組織具有一致厚度且其表現增加量之過度增殖細胞以及促發炎性標記(例如牛皮癬素(psoriasin)、抑彈性酶蛋白(elafin)、人類β-防禦素-2(beta-defensin-2)及LL-37等)(Ayehunie等人,2012)。組織之促發炎性條件提示吾人測試本發明胜肽,以檢查其是否調節發炎性反應。由於該組織模型之成本較高,選擇代表性胜肽SEQ ID NO 1 HB2233作為使用SOR-300-FT組織模型之概念研究之證據。利用HB2233以200μg/ml一式兩份處理SOR-300-FT組織。研究總共12種與牛皮癬病狀相關之基因標記。該研究係同時採用卡泊三醇(calcipotriol)平行運行。qPCR分析顯示,在處理72hr後,SEQ ID NO
1(HB2233)使在發炎牛皮癬皮膚中過度表現之LL-37之表現量顯著下調(3.7倍)(表5)。牛皮癬藥物卡泊三醇顯著下調HBD-2(9.0倍)及牛皮癬素(2.3倍)。HB2233及卡泊三醇下調負責牛皮癬皮膚中之角質細胞之過度增殖及早熟之Ki67表現。另外,SEQ ID NO 1(HB2233)亦下調CXCL1(GRO α)及CXCL5(ENA-78)表現,與正常健康皮膚相比,此二者之表現在牛皮癬皮膚中均顯著上調(Ayehunie S.,2012),然而,卡泊三醇似乎不影響兩種基因之含量。此明顯表示HB2233可為經由與目前用於治療發炎性皮膚病(例如牛皮癬)之藥物卡泊三醇不同之機制產生作用之新穎治療劑。
為更佳理解相同胜肽影響正常健康皮膚組織之方式,將SEQ ID NO:1 HB2233置於基因剖析研究中,該研究係由Sunny Biodiscovery(Santa Paula,CA)實施並使用自MatTek公司(Ashland,MA)購得之EPIDERMTM
正常人類皮膚替代物。先使皮膚替代物平衡過夜後,再依一式兩份,使用胜肽或水對照物處理24hr。在處理結束後,萃取RNA並使其經受PCR陣列分析。如表6中所顯示,SEQ ID NO 1 HB2233刺激參與ECM合成之基因(膠原及整合素)。如人們所預期,其調節趨化因子(CXCL11及MAPK3等)及生長因子(TGF-β1及VEGF等)。基因剖析研究支持活體外觀測到之本發明胜肽調節細胞增殖、血管生成及傷口癒合活性之活性。
使用標準Fmoc(9-茀基甲氧基羰基)固相化學物合成本發明中所包括之所有胜肽。該等胜肽可使用標準胺基酸製備為醯胺化或游離酸序列形式。羧基末端之醯胺化可使得本發明胜肽對蛋白酶降解較不敏感並與游離酸形式相比增加其溶解度,從而提供升高之治療效能。該等胜肽可包含L-或D-胺基酸鏡像異構物,含有一種鏡像異構物形式或兩種形式之組合之殘基。該等胜肽可在N末端及C末端經改質。例如,據論述N末端脂化或乙醯化可改良跨越皮膚之胜肽滲透而不會改
變胜肽之生物活性功能(Samah,2011)。因此,胜肽亦可經脂化,此可提供增強之皮膚滲透。可用於提供本發明化合物之C12-18脂質組份之飽和或不飽和脂肪酸之實例包括月桂酸、肉豆蔻酸、棕櫚酸、硬脂酸、肉豆蔻油酸、棕櫚油酸、油酸及亞麻油酸。胜肽之羧基末端可利用酸(-COOH)或醯胺化(例如,-CONH2、-CONHR或-CONR2)改質。羧基末端之醯胺化可使得本發明胜肽對蛋白酶降解較不敏感並與游離酸形式相比增加其極性,從而提供升高之治療效能。而且,通常可經改質之胜肽官能團包括羥基、胺基、胍、羧基、醯胺、酚、咪唑環或巰基。
胜肽亦可偶聯至可溶性或不可溶性載體分子以根據需要改質其溶解度性質並增加靶向組織中之胜肽之局部濃度。可溶性載體分子之實例包括(但不限於)聚乙二醇(PEG)與聚乙烯吡咯啶酮之聚合物;不可溶性聚合物之實例包括(但不限於)矽酸鹽、聚苯乙烯及纖維素。胜肽可使用脂質體技術或經由奈米技術經微囊化以增強其穩定性並用於控制釋放。對於以上方案,胜肽一般可使用熟習此項技術者所已知之任何方法、例如如下文獻中所揭示之方法產生:Merrifield(J Am Chem Soc.
85:2149,1963);Carpino等人(J Org Chem.
51:3732,1986);Merrifield等人(Anal Chem.
38:1905,1966);或Kent等人[High Yield化學合成Of Biologically Active Peptides On An Automated Peptide Synthesizer Of Novel Design
,IN:PEPTIDES 1984(Ragnarsson編輯)Almqvist and Wiksell Int.,Stockholm(Sweden),第185頁至第188頁],其均以引用方式全文併入本文中。
本發明係關於使用上文所闡述胜肽(例如)用於在調配物中或作為治療劑之方法。該等方法可涉及使用單一胜肽或多個胜肽之組合。在某些情況下,本發明組合物可安置於置於皮膚之上、其中或其下方之裝置內。該等裝置包括以藉由被動或主動釋放機制接觸皮膚或毛囊之
方式釋放該等物質之透皮貼劑、植入物及注射劑。在本文中所闡述方法之用於遞送胜肽之組合物可呈氣溶膠、乳液、液體、洗劑、溶液、凝膠、微囊體、乳膏、膏糊、油膏、粉劑、發泡體或其他醫藥上可接受之調配物之形式。此外,胜肽可使用較少涉及之調配物(例如去離子/蒸餾水、PBS或標準醫用鹽水溶液)遞送。
該調配物可視情況具有化妝品吸引力及/或含有其他試劑,例如類視色素、維生素C或可用作用於本發明胜肽之治療作用之佐劑之其他胜肽。亦可將抗生素添加至該調配物中以避免感染,從而容許發生最大癒合進程。
該調配物可含有蛋白酶抑制劑。蛋白酶抑制劑可經選擇以特異性標靶預期將降解所選擇生物活性胜肽之蛋白酶;此一選擇將基於生物活性胜肽之長度及/或序列來決定。然而,蛋白酶抑制劑未必需要以任何具體方式選擇;例如,在本發明中可採用含有兩種或更多種抑制劑之蛋白酶抑制劑混合物(cocktail)。可將以下類型之蛋白酶抑制劑納入本發明中:絲胺酸蛋白酶抑制劑、半胱胺酸蛋白酶抑制劑、天冬胺酸蛋白酶抑制劑、金屬蛋白酶抑制劑、硫醇蛋白酶抑制劑及蘇胺酸蛋白酶抑制劑。本發明中所用之蛋白酶抑制劑可為胜肽或蛋白質或化學物。該等抑制劑之非限制性實例為絲胺酸蛋白酶抑制劑(抗胰蛋白酶),其包括α-1-抗胰蛋白酶、補體1-抑制劑、抗凝血酶、α-1-抗胰凝乳蛋白酶、纖維蛋白溶酶源活化劑抑制劑1及神經絲胺酸蛋白酶抑制劑;或可用作用於本發明胜肽之治療作用之佐劑之化學物,包括(但不限於)熊果酸及傳明酸(tranexamic acid)。
通常,醫藥上可接受之調配物將包括適於在人類皮膚上使用之任何載體。該等醫藥上及美容上可接受之載體包括乙醇、二甲亞碸、甘油、二氧化矽、氧化鋁、澱粉及等效載體及稀釋劑。該調配物可視情況具有化妝品吸引力及/或含有其他試劑,例如類視色素或可用作
用於本發明胜肽之治療作用之佐劑之其他胜肽。亦可將抗生素添加至該調配物中以避免感染,從而容許發生最大癒合進程。該組合物中之胜肽之濃度可為約0.1μg/mL至約500μg/mL或約0.1μg/mL至約10%;然而,所採用之極限濃度可在該等範圍之外有所不同,此取決於傷口/組織情況之性質、本發明胜肽之生物活性及使用任何佐劑或技術以獲得增強之組合物吸收。CTFA Cosmetic Ingredient Handbook第二版(1992)闡述眾多種在皮膚護理行業中常用之非限制性化妝品及醫藥成份,其適宜用於本發明之組合物中。該等成份類別之實例包括:研磨劑、吸收劑、美容組份(例如香味劑、顏料、著色劑(coloring/colorant)、精油、皮膚感知劑、收斂劑等(例如,丁香油、薄荷腦、樟腦、桉樹油、丁香酚、乳酸甲酯、金縷梅精))、抗痤瘡劑、抗結塊劑、消泡劑、抗微生物劑(例如,丁基胺基甲酸碘丙酯)、抗氧化劑、黏結劑、生物添加劑、緩衝劑、增積劑、螯合劑、化學添加劑、化妝品殺生物劑、變性劑、藥物收斂劑、外用止痛劑、成膜劑或材料、失透劑、pH調整劑、推進劑、還原劑、鉗合劑、皮膚漂白劑及美白劑(例如,氫醌、曲酸、抗壞血酸、抗壞血酸磷酸鎂、抗壞血酸葡萄糖胺)、皮膚調理劑(例如,保濕劑)、皮膚安撫劑及/或癒合劑(例如,泛醇及其衍生物、蘆薈、泛酸及其衍生物、尿囊素、沒藥醇及甘草酸二鉀)、皮膚治療劑、增稠劑及維生素及其衍生物。
可向人類及動物(包括所有哺乳動物)進行本發明胜肽及相關組合物之投與。亦可與典型及/或實驗材料(例如組織移植物、皮膚替代物、組織培養產物及敷料)組合施加。實例包括(但不限於)紗布(製造及非織造、經浸漬、不黏連、填塞、清創);壓迫繃帶及系統;傷口填充物及清潔劑;接觸層;膠原;羊膜;非細胞人類真皮;非細胞基質及組合產品;及多種常用敷料。
常用敷料之列表
通常,該組合物可局部、經口、經皮、全身性或藉由熟習此項技術者所已知之可用於向標靶組織遞送本發明胜肽之之任何其他方法投與。例如,組合物亦可以活體外或離體方式施加至在培養中生長之細胞或患者移植物中。
本發明之組合物可含有一或多種發揮皮膚護理活性之額外試劑。除生物活性胜肽組份以外,本發明可含有其他活性劑,例如玻尿
酸、菸鹼醯胺、植烷三醇、菌綠烯醇、沒藥醇、柳酸、網膜醇、網膜酸、α羥酸、抗壞血酸及微藻酸。預期某些額外活性劑將與生物活性胜肽組份協同起作用,或將增強該調配物之存架壽命。
此外,胺基酸之縮寫遵循習用用法:
關於調配及投與醫藥之技術之細節可參見Remington’s Pharmaceutical Sciences(Maack Publishing公司,Easton,Pa.)之最新版本。儘管局部遞送係合意的,但存在其他遞送方式,例如:經口、非經腸、氣溶膠、肌內、皮下、經皮、髓內、鞘內、心室內、靜脈內、腹膜內或鼻內投與。本發明可調配於多種載體媒劑中,例如,噴霧;
氣溶膠;油包水型乳液;水包油型乳液;面霜或體霜;防曬洗劑或曬後洗劑;或其他局部投與媒劑。另外,本發明之胜肽及含有其之組合物可提供納入一般皮膚護理及化妝品調配物之有用特性,該等調配物係例如多種皮膚化妝品、皮膚乳膏、洗劑、防曬液及治療洗劑或乳膏(例如抗痤瘡調配物)。
本發明之胜肽可用於治療皮膚之傷口。當表皮層自(例如)撕裂、燒傷或水皰破壞時,發生皮膚及黏膜組織損害。損傷亦可涉及壓傷或挫傷,其涉及組織損害而無表皮之併發裂傷。皮膚感染以及某些慢性疾病(例如癌症及自體免疫疾病)亦可能需要表皮表面上之損傷。潰瘍(例如影響糖尿病之彼等或與壓褥瘡相關之彼等)為皮膚損傷之另一形式;該等傷口通常極難醫治,發炎,易於感染,並需要一段時間之癒合過程。潰瘍或其他類型之慢性傷口之存留係由於參與癒合及新血管生成之細胞過程因受損血管生成能力而導致之失敗所致。血管生成係因應缺氧或氣體刺激物而形成新毛細血管網絡(微血管)之過程(Folkman等人,1992)。該過程涉及自缺氧內皮及支撐外被細胞二者局部分泌誘導心血管之內皮增殖及發芽之血管生成因子。不足血管生成對受損傷口癒合及皮膚潰瘍有所貢獻(Galiano等人,2004)。傷口癒合失敗亦可為因傷口邊界處之角質細胞不會遷移以閉合或覆蓋痤瘡之事實而不能使病灶部分地形成上皮之結果(Enoch及Price,2004)。部分地藉助活化基底角質細胞來協調皮膚及黏膜傷口之癒合。在活化時,在稱為上皮形成之過程中定位於傷口周邊處之角質細胞遷移以在傷口上形成單層。已顯示,在慢性傷口之不癒合邊緣處之角質細胞為過度增殖的但不遷移的,且缺乏遷移導致不能形成上皮並在慢性潰瘍之發病機制中起重要作用(Harsha等人,2008)。本發明亦可用於治療與皮膚及黏膜組織中之角質細胞相關之損害。術語「相關黏膜組織」
係指以與皮膚類似之方式組織之任何組織並含有包括(但不限於)與口、鼻、喉、耳、肛門、生殖器及眼睛之眼瞼結膜相關之內襯表面之上皮細胞/角質細胞。可影響該等組織並適於利用本發明胜肽治療之傷口或病灶/損傷之實例為擦傷、水皰、燒傷、撕裂、刺傷、潰瘍、挫傷、皮疹及瘢痕。外科後創傷亦可利用該等胜肽來治療。
另一種表皮損害形式較輕微且係經過長時間產生,最終使皮膚功能受損,故稱為老化皮膚。誘導皮膚老化之主要過程有兩種;防曬皮膚的內在老化(自然老化)及在日光曝露區域的外在老化(光老化)。內在老化反映遺傳背景且隨時間變化。無論如何,老化皮膚具有以下一或多項共通點:皺紋、細紋、色素沉著過度、紅斑、損失光澤、平滑度、堅實度、膚色透明度及均勻度,及毛孔外觀之變化。除遺傳傾向性以外,造成該等可見體徵之原因亦係由諸如紫外線(UV)及污染等環境刺激物之急性或慢性暴露誘導之各種組織學及細胞學變化。諸如起皺紋、乾燥、變薄、下垂及對挫傷之較高敏感性等化妝品問題為除老化以外亦可因長時間暴露至諸如紫外射線及污染等損害劑而過早發生之表皮損害之常見表面體徵。因此,所揭示胜肽可用於針對由內在及外在刺激物二者引起之老化皮膚相關問題,以防止並修復損害,從而再生健康皮膚組織,來逆轉老化效應。以相關方式,可將胜肽施加至已因暴露至多種諸如日光等外來物而受到損害之組織。本發明亦可在該等方面用作化妝品,以賦與更年輕外觀及肌理。可使得本身未改變或經由化學改質及/或特異化遞送之短胜肽滲透穿過表皮,使其過程可對抗彼等引起皮膚變薄、皺紋、脆弱及粗化/硬化之過程。由於角質細胞為表皮表面之主要組份且在老化及受損皮膚中減少,故預期藉由胜肽之刺激來補充角質細胞即可逆轉前述問題。
皮膚相當富有彈性,但其伸展之能力有限。妊娠紋或紋痕為色度不佳之皮膚上之一種結瘢形式。其係由撕裂真皮所造成,其可能隨
時間減少,但不能完全消失。其先以微紅或紫色紋形式出現,但往往逐漸褪色至較淺範圍。妊娠紋常為與快速生長相關之皮膚快速伸展或快速重量損失之結果。妊娠紋會出現在完全未曾經歷過顯著或過度伸展或膨脹之身體部位之任何地方。大部分常見位置為腹部、***、上臂、腋下、背部、大腿、髖及臀。妊娠紋常為某些人生重要階段(如***及懷孕)之激素變化所造成,但皮質類固醇治療、肥胖、美容外科及大量健身可能導致妊娠紋。在皮質類固醇之作用下,角質細胞及纖維母細胞二者之生長會嚴重受損,且因此與正常皮膚相比,膠原I及III之合成以及纖維連接蛋白合成亦顯著減少高達90%以上(Rogalski等人,2002)。已顯示高劑量皮質類固醇與抗血管內皮生長因子(抗血管生成)療法之組合可使紋痕情況惡化且應加以避免(Wheeler等人,2012)。修復及恢復真皮/表皮部分中之角質細胞之功能可為妊娠紋矯正之關鍵。因此,促進刮傷閉合並刺激對傷口癒合所必需之血管生成之本發明胜肽對於妊娠紋之治療而言為理想的。
角質細胞產生並分泌作為內源性抗生素及在皮膚先天性免疫系統內作為信號傳導分子起作用之抗微生物胜肽(AMP)。AMP為宿主先天性免疫防禦系統之關鍵組份並提供病原性微生物之第一道防線並殺死其。另外,其亦藉由各種機制調節並改質宿主發炎性反應。然而,該等胜肽之異常表現與發炎性皮膚疾病之發病機制相關。目前研究暗示LL-37可在牛皮癬及玫瑰斑之發病機制中起重要作用。
牛皮癬為影響大約2%之一般人群之慢性發炎性皮膚疾病(Lowes等人,2007)。牛皮癬之特徵在於Th1型T細胞及嗜中性球之累積、角質細胞過度增殖及分化以及增強之AMP表皮產生。在牛皮癬性病灶中,許高度表現多AMP,例如組織蛋白酶抑制素(LL-37)、β-防禦素、S100蛋白質、趨化因子、RNA酶7、溶菌酶、抑彈性酶蛋白、嗜中性球明膠酶相關之脂質運載蛋白等等。特定而言,組織蛋白酶抑制
素LL-37在牛皮癬中之發炎皮膚中過度表現,結合至自乾燥細胞釋放之細胞外自體DNA並將自體DNA轉化成漿細胞樣樹突細胞之強效刺激物(Dombrowski等人,2012)。儘管關於LL-37在牛皮癬中之作用具有爭議,但顯然此胜肽誘導培養角質細胞中之促發炎性細胞因子之角質細胞增殖及產生。除牛皮癬以外,LL-37目前已參與全身性紅斑狼瘡及類風濕性關節炎(RA)之發展。LL-37在全身性紅斑狼瘡患者之皮膚中高度表現(Sun等人,2011)。在RA中,嗜中性球粒細胞刺激發炎並藉由釋放細胞毒性劑、AMP、蛋白酶及其他發炎性媒介物來損害關節中之組織。在動物模型中顯示,如與健康關節相比LL-37在患有關節炎之大鼠之RA滑膜中及關節中強烈上調(Hoffmann等人,2012)。HB2233顯著下調LL-37以及若干與發炎高度相關之其他因子之表現的觀測結果表明,本發明胜肽可為包括(但不限於)牛皮癬、全身性紅斑狼瘡及類風濕性關節炎之發炎性病狀之潛在治療劑。
玫瑰斑為成人之一最常見皮膚病。目前觀念表明,諸如UV輻射、熱、冷、壓力、辛辣食物及微生物等已知臨床誘發因子調節類鐸受體(Toll-like receptor)信號傳導,誘導反應性氧物質,而且增強AMP及神經胜肽產生(Kenshi等人,2009;Yamasaki等人,2009)。過量之呈LL-37形式之組織蛋白酶抑制素係報導於玫瑰斑中,玫瑰斑似乎由藉由TLR進行之先天性免疫模式識別及處理hCAP18之蛋白酶之異常功能造成(Yamasaki等人,2007;2011)。與牛皮癬及全身性紅斑狼瘡類似,已推測在玫瑰斑中LL-37之過量存在使能夠藉由漿細胞樣樹突細胞及角質細胞二者識別自體核酸,該兩種細胞可加劇發炎,從而藉由容許自體發炎性信號傳導而對疾病有貢獻(Gilliet等人,2008;Ganguly等人,2009)。藉由本發明胜肽下調SOR-300-FT皮膚組織中之LL-37支持用於改良玫瑰斑中之LL-37相關性發炎性病狀之有希望且潛在有用治療。
除發炎性皮膚病以外,高含量之LL-37亦與若干侵襲性實體腫瘤類型相關。顯示LL-37在人類***腫瘤中隨Gleason評分增加並在骨轉移中逐漸過度表現(Jonathan等人,2011)。在卵巢癌(Coffelt等人,2008)、***癌(Heilborn等人,2005)及肺癌(von Haussen等人,2008)之癌症中得到類似臨床觀測結果。儘管LL-37通常藉由嗜中性球蛋白酶3自其前體人類組織蛋白酶抑制素抗微生物蛋白質-18(hCAP-18)裂解而變得經活化,但有證據表明癌症細胞亦產生酶來以蛋白水解方式裂解其所分泌之與嗜中性球無關之hCAP-18(Srensen等人,2001)。此可解釋癌症中升高之LL-37含量。儘管LL-37參與癌症仍有待闡明,但LL-37增強增殖、血管生成、免於凋亡及上皮間質轉換之性質均可用作癌症之標誌且可由轉型/惡性細胞利用以促進腫瘤生長及轉移。藉由本發明胜肽(例如HB2233)下調LL-37可提供減少LL-37含量、從而防止癌細胞擴散之有效方式。可與癌症藥物組合進一步增強潛在益處。
經細菌之感染可造成敗血症並導致敗血性休克,其特徵在於難治性低血壓及最終多器官衰竭及死亡(Ulevitvh等人,1995)。革蘭氏陽性敗血症已經識別為重要臨床病狀(Ulevitvh等人,1995)。其主因為革蘭氏陽性細菌之細胞壁組份,如肽聚糖(PGN)及脂磷壁酸(LTA)。除敗血性休克以外,LTA亦為其他發炎性病狀之主因。異位性皮膚炎(AD)為常見慢性發炎性皮膚疾病。未完全理解AD之發病機制且組織蛋白酶抑制素(LL-37)表現量及其與濕疹之疾病嚴重性之關聯一直存在爭議。AD患者對葡萄球菌皮膚感染特別敏感,葡萄球菌皮膚感染與其皮膚病之惡化相關。儘管葡萄球菌細菌可使AD惡化之機制尚不清楚,但在藉由角質細胞或免疫細胞之直接感染或與細菌組份或碎片之相互作用後之細胞因子產生似乎起重要作用(Bieber等人,2008)。金黃色葡萄球菌(S.aureus
)感染為皮膚發炎之已知誘發物且可
因細菌或細菌產物之直接侵襲而調節免疫反應。研究指示AD皮膚病灶上高含量之金黃色葡萄球菌LTA(Travers等人,2010)。發現源自AD病灶之洗滌流體誘導鼠類骨髓源DC產生IL-1β、IL-6、IL-10及腫瘤壞死因子-α(Travers JB等人,2010)。本發明胜肽顯示活體外與葡萄球菌LTA之高含量結合,且該活性可提供用於中和在感染或抗生素治療期間自革蘭氏陰性細菌釋放之LTA或LPS之毒性效應以改良與敗血性休克及AD皮膚相關之病狀的有希望治療。
本發明胜肽調節角質細胞上之TGF-β(轉型生長因子β)表現之可能性令人特別感興趣。TGF-β為調控細胞增殖、分化、凋亡、基質重塑、黏著、侵襲及遷移之多效性細胞因子/生長因子。通常,TGF-β1可由許多不同細胞類型來產生。已發現所有TGF-β同種型刺激藉由纖維母細胞進行之細胞外基質蛋白質之合成及周轉。
毛囊為皮膚之整體組份,且每一根毛髮為毛囊之角質化產物。每一毛囊經歷如下活動週期:毛髮生長至最大長度,然後生長停止,且使毛髮脫落並置換。毛髮生長週期之各階段已闡述為毛髮生長初期,其係長生長時期;毛髮生長中期,其係自生長至靜止之過渡時期,持續2週至4週;毛髮生長終期,其係不活動時期,持續2個月至4個月。儘管缺少在人類中之直接證據,但對小鼠之研究表明,抑制角質細胞增殖及誘導TGF-β1產生與毛髮生長中期消退直接有關(Foitzik等人,2000)。在活體外觀測到,分離之組織培養之大鼠及人類毛髮生長初期之毛囊之生長受TGF-β1抑制,此在若干態樣中類似於毛髮生長中期樣轉型之早期。SEQ ID NO 1 HB2233抑制角質細胞生長及調節TGF-β1表現之活性可表明,本發明胜肽可能可用作治療劑來去除不期望毛髮。另外,TGF-β之上調亦藉由下調MITF以及黑色素生成基因而與導致灰發之黑色素細胞未成熟有關(Nishimura等人,2010)。因此,本發明胜肽亦具有用於諸如暗斑脫色或皮膚美白等應用之極大
可能性。
皮贅(ST)、軟纖維瘤、纖維性上皮息肉或垂疣為闡述常見良性皮膚病之所有替代術語,該常見良性皮膚病係由自周圍皮膚突出之一點皮膚組成。組織學上,ST為溫和地覆蓋在棘皮症表皮上之息肉狀病灶,即呈現輕度慢性發炎及無力真皮之鬆散之水腫纖維小管核。皮贅視為皮膚之最常見纖維病灶。儘管未完全理解確切病因,但已報導與肥胖、糖尿病、摩擦、肢端肥大症、器官移植、人類乳頭狀瘤病毒及其他病狀之關聯(Zaher等人,2007)。已證明生長因子及激素以及其受體在皮贅形成中起重要作用(Safoury等人,2010ab)。事實上皮贅係由刺激表皮角質細胞及真皮纖維母細胞增殖之因子造成,阻抑細胞增殖之化合物(例如本發明胜肽)可潛在地用於減緩進程並防止形成皮贅。
本發明包括以下實例以展示本發明之某些較佳實施例。
使人類皮膚角質細胞(ATCC CRL-2404)在補充有5ng/ml人類重組上皮生長因子(EGF)之無血清角質細胞生長培養基(Life Technologies,Grand Island,N.Y.)中生長。將該等細胞接種至12孔板上並使其達到100%融合。使細胞單層饑餓24hr,然後使用P200(200μl)移液管吸頭製備刮傷。洗滌刮傷並在時間0處進行拍照。添加胜肽達20μg/ml之最終濃度。將細胞保持於培育器中37℃、5% CO2
下,培育器具有>90%濕度,當在室溫下在段時間內捕獲影像時除外。在7hr至8hr處理後進行刮傷閉合且結果顯示於表1中。
表1.如使用角質細胞刮傷閉合評估細胞遷移之刺激。在7hr處理後經PBS處理之傷口之閉合區域之百分比取為100%,計算經胜肽處理之傷口閉合並如相對於經PBS處理之傷口來呈現。
為確保胜肽對細胞無細胞毒性,將正常人類表皮角質細胞接種至96孔板。在37℃下在5% CO2
之存在下培育該板,以使得該等細胞生長至>95%融合。將胜肽稀釋至儲備溶液中達50μg/ml、100μg/ml、200μg/ml及500μg/ml之濃度。將細胞培養基利用含有多種濃度之胜肽之新鮮培養基置換,然後在37℃及5% CO2
下培育24hr。在處理結束時,使用自ATCC(Manassas VA)購得之MTT分析套組量測細胞活力。結果顯示於表1中。在50μg/ml至500μg/ml之濃度下胜肽不改變細胞活力,如使用MTT分析來量測。
使用自Millipore購得之活體外血管生成分析套組實施血管生成分析。簡言之,根據製造商說明書利用ECMATRIXTM
溶液製備基質層。在補充有0.1mg/ml之肝素(Sigma-Aldrich)、30ug/ml之ECGS(Sigma-
Aldrich)及10%胎牛血清(ATCC,Manassas,VA)之完全F12K培養基(ATCC,Manassas,VA)中培養人類臍靜脈內皮細胞(HUVEC)(ATCC,Manassas,VA)。收穫該等細胞並將其再懸浮於完全培養基中。在96孔板中將胜肽與細胞以每孔大約5×103
個至1×104
個細胞混合,然後將細胞接種至聚合ECMATRIXTM
溶液之表面上。將該板在30℃、5% CO2下培育長達9hr至12hr。在倒置光學顯微鏡下定期檢查管形成並以3hr及5hr間隔獲取圖像並如下文所顯示想每一圖案指定數值。
如表2中所顯示。SEQ ID NO 1至7顯著刺激人類臍靜脈內皮細胞上之毛細血管形成。如人們所預期,LL-37係用作陽性對照且其亦刺激血管生成。PBS係用作陰性對照且細胞開始遷移並使自身配向,但在5hr處未形成發芽或閉合多邊形。
人類表皮角質細胞上之金黃色葡萄球菌LTA誘導之IL-6刺激。在無血清角質細胞培養基中使人類角質細胞生長至>80%融合。將金黃色葡萄球菌LTA 10ug/ml與每一胜肽(50μg/ml)一起在室溫下預培育30min,然後將該混合物轉移至角質細胞培養物中。使該處理持續24hr。去除懸浮液。在短暫旋轉以去除可能細胞碎片後,根據製造商說明書使用自CellSciences(Canton,MA)購得之ELISA套組使懸浮液經受IL-6測試。如表3中所顯示,SEQ ID NO 1至7明顯中和或拮抗LTA刺激人類皮膚角質細胞上之IL-6表現之效應。
使正常人類皮膚角質細胞(ATCC CRL-2404)生長在補充有5ng/ml人類重組上皮生長因子(EGF)(Life Technologies,Grand Island,N.Y.)之無血清角質細胞生長培養基中。每天用顯微鏡檢查該等細胞。當培養物變成50%至75%融合時,抽吸該板中之培養基並添加0.25%胰蛋白酶/EDTA。當細胞變成圓形並分離時,藉由添加新鮮培養基來中和胰蛋白酶。然後對細胞進行離心並將沈澱物再懸浮於新鮮培養基中。使用血球計計數細胞懸浮液,並藉由添加將100μl之細胞懸浮液至每一孔中來將細胞總數調整至每孔約500個至1000個細胞。通常,使用中心60個孔且利用新鮮培養基填充外面各孔以使蒸發降至最低。當在6hr至8hr培育後細胞在每一孔中附接時,一式三份添加100μl含有PBS之新鮮培養基或2×期望濃度之胜肽。然後將微孔板在37℃及5% CO2
下培育48hr至72hr。
在培育結束時,根據製造商說明書使細胞經受CYTOSCANTM
SRB細胞細胞毒性分析(GBiosciences,St.Louis,MO)。簡言之,將細胞固定,然後進行磺醯羅丹明B(SRB)染色。在大量洗滌後,使用增溶緩衝液使該顏色增溶。利用微孔板讀數器在565nm下量測吸光度。表5中所顯示之結果為一式三份處理之平均值且超過對照之±10%之值視為顯著。
由Sunny Biodiscovery Lab(Santa Paula,CA)實施TGF-β刺激。簡言之,使正常新生兒人類表皮角質細胞在cellnTec角質細胞生長培養基(Switzerland)中生長。根據培養基供應商該培養基不含TGF-β。實
驗當日,更新生長培養基並將細胞用50μg/ml之胜肽一式三份處理72hr。在處理結束時,將懸浮液去除,活化並使用LEGEND MAXTM總TGF-β1 ELISA套組(Biolegend,Sam Diego,CA)量化。
將SOR-300-FTTM
組織轉移至含有0.9ml之預升溫分析培養基之6孔板中並平衡至標準培養條件(37℃,5% CO2
)並持續1小時。在1hr平衡後,如以下用新鮮培養基再餵養該等組織:1)對於24hr時間點,用0.9ml之培養基餵養組織,且2)對於>24hr之時間點,藉由將將細胞培養杯置於洗滌器(零件號EPI-WSHR,MatTek公司)頂部來用5ml之培養基餵養組織。接著,將50μl之測試物件局部施加至牛皮癬性組織(n=3),且將測試物件以由贊助商選擇之3個濃度添加至培養基中。在24小時及48小時時間:a)用300μL至400μL之PBS將組織局部沖洗3×,b)用無菌鉗緊密固持含有該等組織之杯且藉由將該杯浸漬於
PBS中來溫和地沖洗測試物件並自杯傾倒出培養基,且c)在沖洗及傾倒後立即將新鮮測試物件再施加至組織(局部地50μL)。在t=72hr處實施分析(3×重複施加)。生成cDNA使用Qiagen RT2第一鏈套組(目錄編號330401)。使用Qiagen RT2 SYBR Green qPCR Mastermix(目錄編號330502)及Qiagen RT2引物量測相對基因表現。使用Bio-Rad CFX軟體實施分析。
使用由Sunny Biodiscovery公司(Santa Paula,CA)構築之PCR陣列分析84個編碼細胞外基質及黏著分子之基因。簡言之,EPIDERMTM
皮膚替代物(目錄編號EPI-212)係自MatTek(Ashland,MA)獲得並根據製造商說明書處置。在平衡過夜後,改變該培養基並將HB2233(330ug/ml)或水對照一式兩份施加於皮膚組織上並使該處理持續24小
時。在處理結束時,收集組織並將其保存在RNAlater
溶液(Ambion,Austin,TX)中。萃取RNA並利用Illustra mini RNAspin套組(目錄編號95017-489,GE Healthcare,Piscataway,NJ)進行純化。利用Agilent HP-8452A二極體陣列分光光度計在260nm及280nm下評估經純化總RNA。在樣品間平衡RNA之濃度,且藉由實時定量PCR利用BioRad iCycler iQ檢測系統、使用PCR陣列PAHS-121A並利用第一鏈合成套組量測感興趣基因之表現。來自Qiagen之SYBR Green主混合物及PCR電泳條件。在利用RT2 Profiler PCR陣列數據分析3.5版本軟體將基因表現正規化至5種管家基因後,使用效率△△Ct方法用於結果量化。若表現量適當地高(小於30個檢測循環)且在每一一式兩份系列中調節為1.5或更多,則認為有差別地表現基因。
根據本發明無需過多實驗即可獲得並實施本文所揭示及主張之所有組合物及方法。儘管已根據較佳實施例闡述本發明之組合物及方法,但熟習此項技術者應明瞭,可改變該等組合物及/或方法及本文所述方法之步驟或步驟順序,此並不背離本發明之概念、精神及範圍。更具體而言,應明瞭,某些在化學及生理上均相關之試劑可代替本文所述試劑,同時可達成相同或相似結果。熟習此項技術者所瞭解之所有該等類似替代物及修改被視為屬於本發明之範圍內。
本申請案中所確認之所有專利及出版物均以引用方式全文併入本文中。
Ayehunie S.、Hedin C.等人,(2012) development and characterization of 3D psoriatic tissue model. TR#702.第1頁至第5頁.Society of investigative dermatology Meeting 2012。
Bacon K、Baggiolini M等人,(2003) Chemokine/chemokine receptor, nomenclature. Cytokine;21:48-9。
Behm B、Babilas P等人,(2012) Cytokines, chemokines and growth factors in wound healing. J Eur Acad Dermatol Venereol. 26(7):812-20。
Bieber T. Atopic dermatitis. (2008) New Engl J Med. 358(14):1483-1494。
Braunstein, S、Kaplan, G、Gottlieb, AB等人:GM-CSF activates regenerative epidermal growth and stimulates keratinocyte proliferation in human skinin vivo. J Invest Dermatol
1994, 103:601-604。
Coffelt SB、Waterman RS等人,(2008)。Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. Int J Cancer. 2008;122(5):1030-1039。
Dombrowski Y、Schauber J, (2012)。Cathelicidin LL-37: a defense molecule with a potential role in psoriasis pathogenesis. Exp Dermatol. 21(5):327-30。
Enoch S及Price P (2004)。Cellular, molecular and biochemical differences in the pathophysiology of healing between acute wounds, chrnic wounds and wounds in the aged. World Wide Wounds. (worldwidewounds.com/2004/august/Enoch/Pathophysiology-Of-Healing.html)。
Foitzik K、Lindner G等人,(2000)。Control of murine hair follicle regression (catagen) by TGF-β1 in vivo. FASEB J. 14:752-760。
Folkman J、Shing Y (1992)。Review Angiogenesis. J Biol Chem. 1992年6月5日;267(16):10931-4。
Galiano RD、Tepper OM、Pelo CR等人,(2004)。Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol. Jun;164(6):1935-47。
Ganguly D、Chamilos G、Lande R等人,(2009)。Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med. 8月31日;206(9):1983-94。
Gangavarapu P、Rajagopalan L、Kolli D等人,(2012)。The monomer-dimer equilibrium and glycosaminoglycan interactions of chemokine CXCL8 regulate tissue-specific neutrophil recruitment. J Leukoc Biol. 91(2):259-65。
Gilliet M及Lande R(2008)。Antimicrobial peptides and self-DNA in autoimmune skin inflammation. Curr Opin Immunol. 20(4):401-7。
Gillitzer R及Goebeler M(2001)。Review Chemokines in cutaneous wound healing. J Leukoc Biol. 69(4):513-21。
Handel TM、Johnson Z、Crown SE等人,(2005)。Review Regulation of protein function by glycosaminoglycans--as exemplified by chemokines. Annu Rev Biochem.;74:385-410。
Harsha A、Stojadinovic O、Brem H等人,(2008)。ADAM12: a potential target for the treatment of chronic wounds. J Mol Med (Berl)。86(8):961-9。
Heilborn JD、Nilsson MF等人,(2005)。Antimicrobial protein hCAP18/LL-37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells. Int J Cancer. 114(5):713-719。
Hoffmann MH、Bruns H等人,(2012)。The cathelicidins LL-37 and rCRAMP are associated with pathogenic events of arthritis in humans and rats. Ann Rheum Dis. 2012年11月29日。[先於印刷之電子出版]
Kaplan, G、Walsh, G、Guido, LS等人:Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing.J Exp Med
1992, 175:1717-1728。
Keeley EC、Mehrad B及Strieter RM (2008)。Chemokines as
mediators of neovascularization. Arterioscler Thromb Vasc Biol. 28(11):1928-36。
Keeley EC、Mehrad B、Strieter RM (2011)。Chemokines as mediators of tumor angiogenesis and neovascularization. Exp Cell Res. 317(5):685-90。
Key K (2003)。Arrest chemokines. Microcirculation;10:289-95。
Mann A、Breuhahn K、Schirmacher P、Blessing M. Keratinocyte-derived granulocyte-macrophage colony stimulating factor accelerates wound healing: Stimulation of keratinocyte proliferation, granulation tissue formation, and vascularization. J Invest Dermatol. 2001年12月;117(6):1382-90。
Lin HY、Tang CH等人,(2010)。Peptidoglycan enhances proinflammatory cytokine expression through the TLR2 receptor, MyD88, phosphatidylinositol 3-kinase/AKT and NF-kappaB pathways in BV-2 microglia. Int ImmunopharmacoL. 10(8):883-91。
Lowes MA、Bowcock AM、Krueger JG (2007)。Review Pathogenesis and therapy of psoriasis. Nature. 445(7130):866-73。
Nishimura EK、Suzuki M等人,(2010)。Key roles for transforming growth factor beta in melanocyte stem cell maintenance. Cell Stem Cell. 6(2):130-40。
Ono SJ、Nakamura T等人,(2003)。Chemokines: roles in leukocyte development, trafficking, and effector function. J Allergy Clin Immunol. 111:1185-99。
Proudfoot AE (2006)。The biological relevance of chemokine-proteoglycan interactions. Biochem Soc Trans. 34(Pt 3):422-6。
Raman D、Sobolik-Delmaire T、Richmond A(2011)。Chemokines
in health and disease. Exp Cell Res. 317(5):575-89。
Rees, RS、Robson, MC、Smiell, JM、Perry, BH: Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.Wound Repair Regen
1999, 7:141-147,Rogalski C等人,(2002)。Extensive striae distensae as a result of topical corticosteroid therapy. Acta Derm Venereol, 83:54-55
Romagnani P、Lasagni L、Annunziato F等人,(2004)。Review CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol. 25(4):201-9。
Rossi D及Zlotnik A(2000)。The biology of chemokines and their receptors. Annu Rev Immunol. 18:217-42。
Safoury O El、M Fawzi等人,(2010a)。Increased tissue leptin hormone level and mast cell count in skin tags: A possible role of adipoimmune in the growth of benign skin growths. Indian J Dermatol Venereol Leprol. 76 (5):538-542。
Safoury O El、Rashid L及Ibrahim M, (2010b)。A study of androgen and estrogen receptors α, β in skin tags. Indian J Dermatol. 2010 55(1): 20-24。
Stagno, F、Guglielmo, P、Consoli, U、Fiumara, P、Russo, M、Giustolisi, R: Successful healing of hydroxyurea-related leg ulcers with topical granulocyte-macrophage colony-stimulating factor.Blood
1999, 94:1479-1480。
Srensen OE、Follin P、Johnsen等人,(2001)。Human cathelicidin, hCAP-18 is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood. 97(12):3951-3959。
Sun CL.、Zhang FZ等人,(2011)。LL-37 expression in the skin in
systemic lupus erythematosus. Lupus. 20(9):904-11。
Travers JB、Kozman A、Mousdicas N等人,(2010)。Infected atopic dermatitis lesions contain pharmacologic amounts of lipoteichoic acid. J Allergy Clin Immunol. 125(1):146-52。
Ulevitch RJ、Tobias PS, (1995)。Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol. 1995; 13:437-57。
von Haussen J、Koczulla R等人,(2008)。The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. Lung Cancer. 59(1):12-23。
Voskaridou, E、Kyrtsonis, MC、Loutradi-Anagnostou, A: Healing of chronic leg ulcers in the hemoglobinopathies with perilesional injections of granulocyte-macrophage colony-stimulating factor.Blood
1999, 93:3568-3569,Wheeler H、Black J、Webb S、Shen H, (2012)。Dehiscence of corticosteroid-induced abdominal striae in a 14-year-old boy treated with bevacizumab for recurrent glioblastoma. J Child NeuroL. 27(7):927-9。
Kenshi Yamasaki、Richard L. Gallo, (2009)。The molecular pathology of rosacea.以最後之編輯形式出版:J Dermatol Sci. 55(2): 77-81。
Yamasaki K、Gallo RL (2011)。Rosacea as a disease of cathelicidins and skin innate immunity. J Investig Dermatol Symp Proc. 12月;15(1):12-5。
Yamasaki K、Di Nardo A、Bardan A等人,(2007)。Increased serine protease activity and cathelicidin promotes skin inflammation in
rosacea. Nat Med. 13(8):975-80。
Zaher H、El Safoury OS、El Komy MM等人,(2007)。Mahmoud SB, Abd El Hamid H. Study of mast cell count in skin tags. Indian J Dermatol. 52:184-7。
<110> 美商赫里克斯生物醫療公司
<120> 可用於治療多種皮膚病之衍生自人類C-X-C趨化因子之四胜肽
<130> 20226.0050.NPTW00
<150> US 61/835,424
<151> 2013-06-14
<160> 7
<170> PatentIn version 3.5
<210> 1
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 來自C-X-C趨化因子之CAG結合區之四胜肽
<400> 1
<210> 2
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 來自C-X-C趨化因子之CAG結合區之四胜肽
<400> 2
<210> 3
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 來自C-X-C趨化因子之CAG結合區之四胜肽
<400> 3
<210> 4
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 來自C-X-C趨化因子之CAG結合區之四胜肽
<400> 4
<210> 5
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 來自C-X-C趨化因子之CAG結合區之四胜肽
<400> 5
<210> 6
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 來自C-X-C趨化因子之CAG結合區之四胜肽
<400> 6
<210> 7
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 來自C-X-C趨化因子之CAG結合區之四胜肽
<400> 7
Claims (22)
- 一種分離之四胜肽,其具有傷口修復及再生活性,其係由胜肽序列(I或V)-X1-K-X2組成,其中X1係E、Q或K,且X2係M、F、I、W、V或L。
- 如請求項1之四胜肽,其為SEQ ID NO:1(IEKM)、SEQ ID NO:2(VEKF)、SEQ ID NO:3(IEKI)、SEQ ID NO:4(IQKI)、SEQ ID NO:5(IKKW)、SEQ ID NO:6(IKKV)或SEQ ID NO:7(IKKL)。
- 如請求項1之四胜肽,其包含L-及D-胺基酸鏡像異構物中之任一者或二者。
- 如請求項1之四胜肽,其係偶聯至載體分子。
- 如請求項1之四胜肽,其係經醯胺化或經脂化。
- 如請求項1之四胜肽,其係呈游離酸形式。
- 一種組合物,其包含至少一種如請求項1至6中任一項之四胜肽及醫藥上可接受之載體。
- 如請求項7之組合物,其中該四胜肽係以在約0.1μg/mL至約500μg/mL之範圍內之濃度存在。
- 如請求項7之組合物,其中該四胜肽係以在約0.1μg/mL至約20mg/mL之範圍內之濃度存在。
- 如請求項7之組合物,其中該組合物係呈氣溶膠、乳液、液體、洗劑、溶液、凝膠、微囊體、乳膏、膏糊、油膏、粉劑或發泡體之形式。
- 如請求項7之組合物,其中該組合物係納入適於施加至皮膚表面或施加於皮膚組織下方之裝置中。
- 一種組合物,當其依治療有效量施加有效時間量時,可以為哺乳動物癒合傷口或治療發炎性皮膚病,其中該藥品包含醫藥上 可接受之載體及至少一種如請求項1至6中任一項之四胜肽。
- 如請求項12之組合物,其中該傷口或發炎性病狀影響該哺乳動物之皮膚或相關黏膜組織。
- 如請求項13之組合物,其中該傷口係由於擦傷、水皰、燒傷、撕裂、潰瘍、挫傷、皮疹、擴張紋痕、瘢痕、妊娠紋或老化或環境暴露之效應所致。
- 如請求項13之組合物,其中該發炎性病狀係由於牛皮癬、異位性皮膚炎及玫瑰斑所致。
- 如請求項13之組合物,其中該發炎性病狀係由於去除毛髮或去除皮贅所致。
- 如請求項7至16中任一項之組合物,其用於皮膚護理治療。
- 如請求項7至16中任一項之組合物,其用於化妝品產品。
- 一種如請求項1至16中任一項之四胜肽或組合物之用途,其用於製造用以治療皮膚或相關黏膜組織之傷口或發炎性病狀之藥品。
- 如請求項19之用途,其中該傷口係由於擦傷、水皰、燒傷、撕裂、潰瘍、挫傷、皮疹、擴張紋痕、瘢痕、妊娠紋或老化或環境暴露之效應所致。
- 如請求項19之用途,其中該發炎性病狀係由於牛皮癬、異位性皮膚炎及玫瑰斑所致。
- 如請求項19之用途,其中該發炎性病狀係由於去除毛髮或去除皮贅所致。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361835424P | 2013-06-14 | 2013-06-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201503896A TW201503896A (zh) | 2015-02-01 |
TWI511737B true TWI511737B (zh) | 2015-12-11 |
Family
ID=50943603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW103120387A TWI511737B (zh) | 2013-06-14 | 2014-06-12 | 可用於治療多種皮膚病之衍生自人類c-x-c趨化因子之四胜肽 |
Country Status (22)
Country | Link |
---|---|
US (1) | US10195245B2 (zh) |
EP (1) | EP3007716B1 (zh) |
JP (1) | JP6416240B2 (zh) |
KR (1) | KR102254260B1 (zh) |
CN (1) | CN105324122B (zh) |
AR (1) | AR096594A1 (zh) |
AU (1) | AU2014278708B2 (zh) |
BR (1) | BR112015031018B1 (zh) |
CA (1) | CA2915174C (zh) |
CY (1) | CY1119191T1 (zh) |
DK (1) | DK3007716T3 (zh) |
ES (1) | ES2631804T3 (zh) |
HK (1) | HK1217436A1 (zh) |
HU (1) | HUE032970T2 (zh) |
MX (1) | MX362846B (zh) |
MY (1) | MY168981A (zh) |
PL (1) | PL3007716T3 (zh) |
RU (1) | RU2687151C2 (zh) |
SG (1) | SG11201509048VA (zh) |
SI (1) | SI3007716T1 (zh) |
TW (1) | TWI511737B (zh) |
WO (1) | WO2014200651A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110302088A (zh) * | 2019-04-29 | 2019-10-08 | 杭州肽佳生物科技有限公司 | 一种包含修饰芋螺肽的化妆品组合物 |
KR20220130144A (ko) * | 2020-01-21 | 2022-09-26 | 에이에스씨 리제니티 리미티드 | 피부의 외관 및 재생을 개선시키는 신규한 펩티드를 포함하는 국소 투여용 화장 제형 |
PL245202B1 (pl) | 2020-03-06 | 2024-06-03 | Gdanski Univ Medyczny | Lipopeptydowe koniugaty i ich sole, sposób wytwarzania lipopeptydowych koniugatów i ich soli, kompozycja farmaceutyczna zawierająca lipopeptydowy koniugat i jego sole do leczenia ran przewlekłych |
WO2022098051A1 (ko) | 2020-11-05 | 2022-05-12 | 한국생명공학연구원 | 항염 및 조직 재생작용을 갖는 신규 펩타이드 |
CN113698452B (zh) * | 2021-08-23 | 2023-08-18 | 四川丽妍工坊生物科技有限公司 | 一种促皮肤修复肽、制备方法及其应用 |
CA3233983A1 (en) * | 2021-11-02 | 2023-05-11 | Ole-Jan Iversen (Deceased) | Tri-, tetra and pentapeptides, compositions thereof and their use in the therapy of psoriasis |
WO2023214802A1 (ko) * | 2022-05-03 | 2023-11-09 | 한국생명공학연구원 | 신규 펩타이드 및 이의 항염 및 재생 용도 |
KR20240086709A (ko) * | 2022-11-18 | 2024-06-19 | (주)케어젠 | 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101472944A (zh) * | 2006-06-13 | 2009-07-01 | 赫里克斯生物医疗公司 | 用于诱导细胞外基质蛋白合成的肽片段 |
CN101855235A (zh) * | 2007-10-29 | 2010-10-06 | 赫里克斯生物医疗公司 | 保护性皮肤护理四肽 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991013904A1 (en) * | 1990-03-05 | 1991-09-19 | Cephalon, Inc. | Chymotrypsin-like proteases and their inhibitors |
FR2814076B1 (fr) | 2000-09-21 | 2002-12-20 | Centre Nat Rech Scient | Agent angiogenique et ses utilisations |
ZA200802546B (en) | 2005-08-29 | 2009-10-28 | Healor Ltd | Methods and compositions for prvention and treatment of diabetic and aged skin |
JP2007001981A (ja) | 2006-07-10 | 2007-01-11 | Nippon Meat Packers Inc | 皮膚組織の再生及び肌質改善効果のあるペプチドを含有する化粧品 |
CN101679495B (zh) | 2007-01-05 | 2013-07-17 | 赫里克斯生物医疗公司 | 用于细胞学和免疫学调节的短的生物活性肽 |
EP2109054A1 (en) * | 2008-04-09 | 2009-10-14 | Biotempt B.V. | Methods for identifying biologically active peptides and predicting their function |
TWI429451B (zh) | 2011-10-26 | 2014-03-11 | Nat Univ Tsing Hua | 對具有elr-cxc趨化素高度親和力的受體蛋白細胞所引發疾病之拮抗治療劑 |
-
2014
- 2014-05-14 DK DK14730697.1T patent/DK3007716T3/en active
- 2014-05-14 SG SG11201509048VA patent/SG11201509048VA/en unknown
- 2014-05-14 CN CN201480033362.9A patent/CN105324122B/zh active Active
- 2014-05-14 US US14/907,811 patent/US10195245B2/en active Active
- 2014-05-14 JP JP2016519511A patent/JP6416240B2/ja active Active
- 2014-05-14 KR KR1020157037042A patent/KR102254260B1/ko active IP Right Grant
- 2014-05-14 RU RU2015146679A patent/RU2687151C2/ru active
- 2014-05-14 EP EP14730697.1A patent/EP3007716B1/en active Active
- 2014-05-14 CA CA2915174A patent/CA2915174C/en active Active
- 2014-05-14 HU HUE14730697A patent/HUE032970T2/en unknown
- 2014-05-14 AU AU2014278708A patent/AU2014278708B2/en active Active
- 2014-05-14 MY MYPI2015704511A patent/MY168981A/en unknown
- 2014-05-14 PL PL14730697T patent/PL3007716T3/pl unknown
- 2014-05-14 MX MX2015017089A patent/MX362846B/es active IP Right Grant
- 2014-05-14 BR BR112015031018-4A patent/BR112015031018B1/pt active IP Right Grant
- 2014-05-14 ES ES14730697.1T patent/ES2631804T3/es active Active
- 2014-05-14 SI SI201430262T patent/SI3007716T1/sl unknown
- 2014-05-14 WO PCT/US2014/037978 patent/WO2014200651A1/en active Application Filing
- 2014-06-12 TW TW103120387A patent/TWI511737B/zh active
- 2014-06-12 AR ARP140102248A patent/AR096594A1/es not_active Application Discontinuation
-
2016
- 2016-05-12 HK HK16105420.1A patent/HK1217436A1/zh unknown
-
2017
- 2017-06-22 CY CY20171100663T patent/CY1119191T1/el unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101472944A (zh) * | 2006-06-13 | 2009-07-01 | 赫里克斯生物医疗公司 | 用于诱导细胞外基质蛋白合成的肽片段 |
CN101855235A (zh) * | 2007-10-29 | 2010-10-06 | 赫里克斯生物医疗公司 | 保护性皮肤护理四肽 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI511737B (zh) | 可用於治療多種皮膚病之衍生自人類c-x-c趨化因子之四胜肽 | |
KR101668803B1 (ko) | 보호용 피부 관리 테트라펩티드 | |
JP6348126B2 (ja) | 創傷治癒を促進する生物活性短鎖ペプチド | |
ES2404669T3 (es) | Péptidos bioactivos cortos para modulación celular e inmunológica | |
ZHANG et al. | GCC PATENT APPLICATION |